Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

ClinicalTrials.gov ID: NCT00689936

Public ClinicalTrials.gov record NCT00689936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.

Study identification

NCT ID
NCT00689936
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Celgene
Industry
Enrollment
1,623 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 20, 2008
Primary completion
Jul 13, 2016
Completion
Jul 13, 2016
Last update posted
Nov 19, 2019

2008 – 2016

United States locations

U.S. sites
32
U.S. states
17
U.S. cities
28
Facility City State ZIP Site status
University of AL Birmingham Birmingham Alabama 35294
Cedar Sinai Medical Center Dept of Medicine Los Angeles California 90048
University of California, San Francisco- California San Francisco California 94143
Stanford University Stanford Stanford California 94305
Gainesville Heme Oncology Associates Gainesville Florida 32607
Baptist Cancer Institute Jacksonville Florida 32207
Integrated Community Oncology Network Orange Park Florida 32073
Gulf Coast Oncology St. Petersburg Florida 33705
Palm Beach Cancer Institute, LLC West Palm Beach Florida 33401
Southern Illinois Hematology Oncology Centralia Illinois 62801
Orchard Healthcare Research, Inc. Chicago Illinois 60611
John H Stroger Hospital of Cook County Chicago Illinois 60612
Rush University Medical Center Chicago Illinois 60612
Ingalls Cancer Institute Harvey Illinois 60426-3558
Cancer Center of Kansas Wichita Kansas 67124
Maine Center for Cancer Medicine Blood Disorders Scarborough Maine 04074
Center for Cancer and Blood Disorders Bethesda Maryland 20817
Mayo Clinic Cancer Center Rochester Minnesota 55905
Billings Clinic Billings Montana 59107
Arena Oncology Associates, PC Lake Success New York 11042
Dakota Cancer Institute Fargo North Dakota 58103
Gabrail Cancer Center Research Canton Ohio 44718
University Hospitals of Cleveland Cleveland Ohio 44106
Cleveland Clinic Cleveland Ohio 44195
Kaiser Permanente Northwest Oncology Hematology Portland Oregon 97227
St. Luke's Hospital and Health Network Allentown Pennsylvania 18104
University of Pennsylvania Philadelphia Pennsylvania 19104
The Cancer Center Collierville Tennessee 38017
University of Tennessee Cancer Institute Memphis Tennessee 38104
University of Texas Medical Branch Galveston Texas 77555-0561
Swedish Cancer Institute Seattle Washington 98104
Fred Hutchinson Cancer Center Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00689936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 19, 2019 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00689936 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →